Cheonan, South Korea, September 14, 2023 – MGI, a company committed to creating foundational tools and technologies to lead life sciences, today announced a memorandum of understanding with Bio-Medical Science Co., Ltd. (“BMS ” to expand genomic solutions in South Korea. taking advantage of MGI’s cutting-edge technology. The MoU is expected to result in collaborations to localize MGI manufacturing capacity in select sequencers and genetic reagents in South Korea through BMS, which will provide the market with cutting-edge products tailored to local needs, thus helping to advance in genomics. research and clinical diagnosis.
Image credit: MGI
“This MoU marks a key milestone for the development of genomics in South Korea, as we introduce localized, high-quality and cost-effective solutions, powered by our proprietary DNBSEQ technology. said Roy Tan, managing director of MGI Asia Pacific. “By joining forces with our partner BMS, MGI aims to facilitate broader adoption of genomics, multiomics, metagenomics and related activities locally in South Korea. »
Under the MoU, BMS and MGI will work towards collaborations related to the licensing, supply, manufacturing and distribution of select sequencers and genetic reagents in South Korea. By leveraging BMS’ strong local sales and distribution network and MGI’s innovative technology, South Korea is poised to further unlock the potential of genomics, clinical studies and even the microbiome on a larger scale.
Image credit: MGI
“Amid a rapidly growing high-throughput sequencing market in South Korea, we are seeing a mismatch between demand and supply and hope to remove barriers to entry by offering products and solutions that have proven to be efficient, convenient and tailored to local needs,” he said. Kangsan D. Kim, director of marketing and communications at BMS. “We are excited to partner with MGI to accelerate the localization of their cutting-edge genomic products, particularly sequencers like DNBSEQ-G99. »
In fact, the relationship between MGI and BMS dates back to 2019, when BMS became the first company in the Asia-Pacific region to join MGI’s Global Sequencer User Program (SUP) to promote the development of genetic technologies and applications. through personalized products and services. . Earlier this year, the two companies also partnered to establish a joint Customer Experience Center (CEC) in South Korea, aimed at giving local customers direct access to the latest MGI technologies and products.
Image credit: MGI
MGI Tech Co., Ltd. (or its subsidiaries, “MGI”), headquartered in Shenzhen, is committed to creating core tools and technologies to lead life sciences through intelligent innovation. Based on its proprietary technology, MGI focuses on the research and development, production and sale of sequencing instruments*, reagents* and related products to support research in life sciences, agriculture, precision medicine and healthcare. sanitary. As of June 30, 2023, MGI had more than 2,800 employees, including 35.2% R&D personnel. Founded in 2016, MGI operates in more than 90 countries and regions, serving more than 2,400 customers. For more information, visit the MGI website or log in to TwitterLinkedIn or YouTube.
Bio-Medical Science Co. Ltd., commonly known as BMS, holds a leading position in Korea’s life sciences distribution industry. Established in 1988, its headquarters is strategically located in Gangnam, Seoul, with a branch network and a dedicated logistics distribution center covering the entire country. Its esteemed clientele includes major academic and government institutions, as well as renowned research and diagnostic centers.
*Products are provided for research purposes only. Do not use in diagnostic procedures (unless otherwise indicated)